<DOC>
	<DOCNO>NCT00234546</DOCNO>
	<brief_summary>The aim clinical study investigate efficacy safety DysportÂ® patient early onset upper limb spasticity within 2-12 week stroke .</brief_summary>
	<brief_title>Asian Botulinum Clinical Trial Designed Early Stroke Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Firstever stroke accord World Health Organisation criterion ( previous transient ischaemic attack clinically silent infarct CT/MRI count previous stroke ) CT/MRI scan require classify ischaemic / haemorrhagic stroke Patient recruit 212 week stroke Modified Ashworth Spasticity Score 1+ either elbow wrist joint The patient bleeding disturbance use coumarin derivatives The patient currently receive drug affect neuromuscular transmission Coexisting severe systemic illness may adversely affect functional outcome Preexisting neuromuscular junction disease neurogenic disorder interfere spasticity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>